A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
Breast Cancer Research2003Vol. 6(1), pp. R8–R17
Citations Over TimeTop 10% of 2003 papers
Mark E. Robson, Pierre O. Chappuis, Jaya M. Satagopan, Nora Wong, Jeff Boyd, John R. Goffin, Clifford A. Hudis, David Roberge, Larry Norton, Louis R. Bégin, Kenneth Offit, William D. Foulkes
Abstract
BRCA1 mutations, but not BRCA2 mutations, are associated with reduced survival in Ashkenazi women undergoing breast-conserving treatment for invasive breast cancer, but the poor prognosis associated with germline BRCA1 mutations is mitigated by adjuvant chemotherapy. The risk for metachronous ipsilateral disease does not appear to be increased for either BRCA1 or BRCA2 mutation carriers, at least up to 10 years of follow up.
Related Papers
- → Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan(1996)502 cited
- → Differences between germline and somatic mutation rates in humans and mice(2017)431 cited
- → The mutational landscape of human somatic and germline cells(2022)13 cited
- → Germline mutations in the Von Hippel‐Lindau disease (VHL) gene in families from North America, Europe, and Japan(1996)42 cited
- → 28. Identification of TP53 germline variants in pediatric patients undergoing tumor testing(2022)